Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Depression

Antidepressants more effective than placebo for adults with acute major depressive disorder

Findings represent the “most comprehensive evidence base currently available” to guide the initial choice about pharmacological treatment for acute major depressive disorder in adults, researchers conclude.

David Taylor, director of pharmacy and pathology at the Maudsley Hospital, in London, and professor of psychopharmacology at King’s College, London

Source: RPS

David Taylor, professor of psychopharmacology at King’s College, London, said the study gave “valuable insights into the small differences between drugs and the large difference between drugs and placebo”.

Antidepressants are more effective than placebo for the acute treatment of adults with unipolar major depressive disorder, according to a new study published in The Lancet (online, 21 February 2018)[1].

Researchers performed a meta-analysis of 522 double-blind, randomised controlled trials, comprising 116,477 patients randomly assigned to 21 antidepressant drugs and placebo. The analysis included both placebo-controlled and head-to-head trials as well as unpublished data.

The researchers found that all antidepressants included in the analysis were more efficacious than placebo in adults with major depressive disorder.

Some of the antidepressants, including escitalopram, mirtazapine, paroxetine, agomelatine and sertraline, had a higher response and lower dropout rate than the other antidepressants.

However, reboxetine, trazodone, and fluvoxamine were found to be less favourable as they were generally associated with lower efficacy and acceptability profiles.

The researchers also noticed that there were smaller differences between drugs when placebo-controlled trials were included in the analysis, but there was more variability in efficacy and drop-out patterns in head-to-head trials, where no placebo was used. One suggested reason for this was that patients randomly assigned to the active drug in a double-blind, placebo-controlled trial might leave studies earlier than in head-to-head studies because they might suspect they have been allocated to the placebo group and not the intervention group.

The researchers highlighted that the findings in adults contrasted with the efficacy of antidepressants in children and adolescents, for whom fluoxetine is the only antidepressant to successfully reduce depressive symptoms.

“Network meta-analyses can tell us a great deal about relative efficacy and acceptability,” said David Taylor, director of pharmacy and pathology at the Maudsley Hospital, in London, and professor of psychopharmacology at King’s College, London.

“This study provides valuable insights into the small differences between drugs and the large difference between drugs and placebo.

“The inclusion of unpublished data is helpful but it is unlikely that all unpublished data have been included. Also, placebo response has increased over time so more recently introduced drugs may have their efficacy underestimated,” he added.

The researchers concluded that the findings represented the most comprehensive evidence base currently available to guide the initial choice about pharmacological treatment for acute major depressive disorder in adults and hoped that the results would assist in shared decision making between patients, carers and their clinicians.

“Taking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions,” said Helen Stokes-Lampard, chair of the Royal College of GPs.

“This research should reassure patients who are taking or are contemplating commencing antidepressants, and the doctors that prescribe them, that they are an effective treatment for depression in the short-term.

“Although antidepressants are of proven benefit — as this study shows — no doctor wants their patients to become reliant on medication so where possible, GPs will explore alternative treatments, such as talking therapies or CBT [cognitive behavioural therapy], which can be of great benefit for some patients.

“However, these services are often hard to come by in the community and we need better, quicker access to them if we’re able to deliver the level of care we want to for all NHS patients,” Stokes-Lampard added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204447

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • fluoxetine pills
  • David Taylor, director of pharmacy and pathology at the Maudsley Hospital, in London, and professor of psychopharmacology at King’s College, London

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.